Tenecteplase for acute ischemic stroke presenting after 4.5 hours (TIMELESS trial)

Tenecteplase (TNKase or TNK) is genetically modified alteplase (tPA). Because it can be infused more rapidly than alteplase, TNK is gaining prominence as thrombolytic treatment for acute ischemic stroke, in patients presenting within 4.5 hours of their last time known to be well.

Limited data have suggested thrombolytics may be beneficial beyond 4.5 hou…